Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $1.7 million.

  • Nurix Therapeutics' Other Accumulated Expenses rose 161.33% to $1.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $1.7 million, marking a year-over-year increase of 161.33%. This contributed to the annual value of $2.3 million for FY2024, which is 202.93% up from last year.
  • Per Nurix Therapeutics' latest filing, its Other Accumulated Expenses stood at $1.7 million for Q3 2025, which was up 66.03% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Other Accumulated Expenses peaked at $2.7 million during Q1 2025, and registered a low of $551,000 during Q1 2022.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.0 million (2023), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Other Accumulated Expenses skyrocketed by 272.71% in 2022, and later slumped by 50.03% in 2023.
  • Nurix Therapeutics' Other Accumulated Expenses (Quarterly) stood at $659,000 in 2021, then spiked by 128.07% to $1.5 million in 2022, then plummeted by 50.03% to $751,000 in 2023, then spiked by 202.93% to $2.3 million in 2024, then skyrocketed by 161.33% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.0 million for Q2 2025, and $2.7 million during Q1 2025.